SequelSEC

Rezolute, Inc. RZLT

Pharmaceutical Preparations · CIK 0001509261 · Fiscal year ends 0630

Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$82.97M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$258.83MMarket value of stock held by non-affiliates, as stated on the cover page for 2024-12-31
Float per share$2.85Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / equity1.6×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2024-12-31, not today, and each multiple below it uses the figures for the fiscal year ending 2025-06-30 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio9.68x89th

Rezolute, Inc. (RZLT) reported net income of -$77.59M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Rezolute, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Rezolute, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-30
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$82.97M-$79.89M-$70.42M-$55.99M-$41.84M-$22.89M-$20.52M-$25.94M-$28.73M-$20.32M
Net income-$77.59M-$74.41M-$68.46M-$51.79M-$41.06M-$20.90M-$20.33M-$30.45M-$29.86M-$20.28M
Research & development$53.80M$61.53M$55.74M$43.81M$32.49M$14.99M$14.45M$19.08M$17.28M$12.09M
Weighted-average diluted sharesshares 103.91Mshares 76.00Mshares 51.47Mshares 51.19Mshares 19.49Mshares 7.67MUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0$0$0$0$0$0
Diluted EPS$-0.75$-0.98$-1.33$-1.01$-2.32$-2.72UnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$29.17M$18.37M$14.68M$12.18M$9.36M$7.91M$6.07M$6.86M$9.10M$8.23M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Rezolute, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-30
Cash & equivalents$10.62M$94.11M$70.40M$16.04M$150.41M$41.05M$77.40M$37.60M$1.65MUnavailable
Total assets$112.85M$175.49M$132.74M$123.72M$152.42M$42.61M$10.96M$12.25M$2.50M$10.63M
Current assets$110.51M$171.14M$128.65M$104.91M$152.10M$41.99M$10.52M$12.14M$2.01M$4.93M
Total liabilities$12.16M$13.36M$11.73M$7.55M$2.95M$16.51M$3.60M$10.50M$6.46M$2.10M
Current liabilities$11.42M$11.91M$9.61M$5.20M$2.46M$1.97M$3.23M$8.38M$6.25M$1.77M
Total equity incl. NCI$100.69M$162.13M$121.00M$116.17M$149.47M$26.10M$7.36M$1.75M-$3.96M$8.53M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailable$13.97M$0$0$3.42MUnavailable
Accounts payable$5.03M$5.81M$4.90M$3.27M$1.13M$1.04M$893.00K$563.00KUnavailableUnavailable

Cash flow

Rezolute, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-30
Operating cash flow-$64.64M-$69.08M-$57.37M-$44.48M-$39.62M-$20.44M-$24.17M-$15.30M-$14.11M-$13.31M
Capital expendituresUnavailableUnavailableUnavailable$153.00KUnavailableUnavailable$0$47.00K$6.00KUnavailable
Investing cash flow-$21.10M-$14.54M$48.70M-$101.46MUnavailable$0$0$231.00K$1.73M-$195.38K
Financing cash flow$2.24M$107.33M$63.03M$11.57M$148.98M$51.53M$22.55M$25.00M$9.54M$13.93M
Net change in cash-$83.49M$23.71M$54.36M-$134.37M$109.36M$31.09M-$1.62M$9.93MUnavailableUnavailable
Stock-based compensation$14.46M$7.12M$7.36M$7.27M$3.68M$3.96M$3.32M$2.64M$5.10M$6.01M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailable$3.00KUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$31.00K$31.00K$36.00K$30.00K$13.00K$13.00K$18.00K$49.00K$1.07MUnavailable

Derived

Rezolute, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-30
Free cash flowUnavailableUnavailableUnavailable-$44.63MUnavailableUnavailableUnavailable-$15.35M-$14.12MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio9.68x14.37x13.39x20.18x61.78x21.34x3.26x1.45x0.32x2.78x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RZLT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-K · Filed 2026-09-24View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-Q · Filed 2026-02-12View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-K · Filed 2025-09-17View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.